Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ProMIS Neurosciences Inc. (PMN)

ProMIS Neurosciences reports blinded interim PMN310 safety and biomarker data in Alzheimer's trial

Neutral Impact 4 of 5 product/contract Written later

ProMIS Neurosciences reported blinded six-month interim safety and biomarker data for PMN310 in its Phase 1b PRECISE-AD trial in early Alzheimer's disease, with no ARIA-E cases reported across 136 safety-evaluable patients. The trial remains blinded and ongoing, and the company said unblinded 12-month topline results, including efficacy data, are expected in the first quarter of 2027. The filing contains no financial results, so the update is clinical data that shareholders will weigh ahead of the readout.

Key points

  • No ARIA-E reported as of the July 22, 2026 data cutoff; 4.4% total ARIA, all mild and asymptomatic (ARIA-H only)
  • 68.5% of patients had a plasma pTau217 decline from baseline and 62.5% had a CSF MTBR-tau243 decline; the company says allocations are still blinded
  • Unblinded 12-month topline results expected in Q1 2027, including efficacy data
  • Webinar held July 28, 2026 at 8:00 a.m. E.T. with KOLs Dr. Will Mantyh and Dr. Michael Weiner

The filing

CompanyProMIS Neurosciences Inc. (PMN)
Form8-K, current report
Filed with the SECJul 28, 2026, 6:05 AM ET
Accession number0001104659-26-087269

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.